PHCUF Stock Chart & Stats
$6.03
-$0.17(-2.75%)
At close: 4:00 PM EDT
$6.03
-$0.17(-2.75%)
Day’s Range― - ―
52-Week Range$4.52 - $8.56
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$134.21M
Enterprise Value$1.37B
Total Cash (Recent Filing)$259.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)25.2
Beta0.38
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.12%
Share Statistics
EPS (TTM)0.02
Shares Outstanding27,120,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap10.23
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda22.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Photocure ASA News
PHCUF FAQ
What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was $4.52 and its highest was $8.56 in the past 12 months.
What is Photocure ASA’s market cap?
Photocure ASA’s market cap is $134.21M.
When is Photocure ASA’s upcoming earnings report date?
Photocure ASA’s upcoming earnings report date is Feb 24, 2027 which is in 116 days.
How were Photocure ASA’s earnings last quarter?
Photocure ASA released its earnings results on Oct 28, 2026. The company reported -$0.106 earnings per share for the quarter.
Is Photocure ASA overvalued?
According to Wall Street analysts Photocure ASA’s price is currently Overvalued.
Does Photocure ASA pay dividends?
Photocure ASA pays a Annually dividend of $0.343 which represents an annual dividend yield of 5.12%. See more information on Photocure ASA dividends here
What is Photocure ASA’s EPS estimate?
Photocure ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Photocure ASA have?
Photocure ASA has 27,120,820 shares outstanding.
What happened to Photocure ASA’s price movement after its last earnings report?
Photocure ASA reported an EPS of -$0.106 in its last earnings report. Following the earnings report the stock price went down -4.104%.
Which hedge fund is a major shareholder of Photocure ASA?
Currently, no hedge funds are holding shares in PHCUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Photocure ASA
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
PHCUF Company Deck
PHCUF Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Photocure reported 7% constant-currency product revenue growth, strong unit and active-account expansion, improving adjusted EBITDA, continued European and North American momentum, progress on FDA reclassification and OEM access, and multiple long-term growth initiatives. The main negatives were foreign-exchange pressure, a quarterly net loss, higher operating expenses, pending CMS and FDA decisions, expected near-term AssureMDx operating losses, and uncertainty around potential generic competition. Management nevertheless raised 2026 guidance and reiterated substantial long-term growth and margin targets.View all PHCUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.22% Mutual Funds
― Other Institutional Investors
99.40% Public Companies and
Individual Investors